IDYA (IDEAYA Biosciences) Accounts Payable: $20.7 Mil (As of Mar. 2026)


IDYA IDEAYA Biosciences Inc IDYA
54 GF Score
Price $37.66
GF Value $205.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Accounts Payable?

IDEAYA Biosciences IDYA +4.12% 54 Accounts Payable is $20.7 Mil as of Mar. 2026. GuruFocus rates IDYA with a GF Score™ of 54/100 and a GF Value™ of $205.30 (Possible Value Trap). The stock has 6 warning signs investors should review.

IDEAYA Biosciences's Accounts Payable for the quarter that ended in Mar. 2026 was $20.7 Mil.

IDEAYA Biosciences's quarterly Accounts Payable declined from Sep. 2025 ($18.4 Mil) to Dec. 2025 ($17.6 Mil) but then increased from Dec. 2025 ($17.6 Mil) to Mar. 2026 ($20.7 Mil).

IDEAYA Biosciences's annual Accounts Payable increased from Dec. 2023 ($6.6 Mil) to Dec. 2024 ($15.4 Mil) and increased from Dec. 2024 ($15.4 Mil) to Dec. 2025 ($17.6 Mil).

IDEAYA Biosciences Accounts Payable Related Terms

IDEAYA Biosciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for IDEAYA Biosciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEAYA Biosciences Accounts Payable Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 2.10 4.28 6.60 15.42 17.58

IDEAYA Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.63 17.27 18.43 17.58 20.74
IDYA
54GF Score
IDEAYA Biosciences Inc IDYA
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEAYA Biosciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $20.7 Mil mean?
IDEAYA Biosciences (IDYA) has a Accounts Payable of $20.7 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on IDEAYA Biosciences and its competitors.
Is IDEAYA Biosciences' Accounts Payable too high?
IDEAYA Biosciences' current Accounts Payable is $20.7 Mil. Overall, IDEAYA Biosciences has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Accounts Payable compare to PBLS and ELVN?
IDEAYA Biosciences' Accounts Payable of $20.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current Accounts Payable is $20.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $205.30, compared to a current price of $37.66 — trading 81.7% below its estimated fair value. The current Accounts Payable is $20.7 Mil. IDEAYA Biosciences' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Accounts Payable is $20.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $37.66 is trading 81.7% below its estimated GF Value™ of $205.30. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • Accounts Payable: $20.7 Mil
  • GF Value™: $205.30 vs. price of $37.66 (81.7% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
54GF Score

Get the complete analysis for IDYA

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.66
Price
$205.30
GF Value